Bellerophon Therapeutics (BLPH) Tops Q3 EPS by 6c

Bellerophon Therapeutics (NASDAQ: BLPH) reported Q3 EPS of ($0.53), $0.06 better than the analyst estimate of ($0.59).

For earnings history and earnings-related data on Bellerophon Therapeutics (BLPH) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Deutsche Bank Upgrades Wickes Group plc (WIX:LN) to Hold
• Redburn upgrades Southwest, stays bullish on Delta and United